Skip to main content

Table 1 Patient characteristics

From: Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma

Patient characteristicsHCCnon-HCC malignanciesnon-HCC benign lesions
No. of patients1653016
No. of lesions1733224
Sex (male)133 (80.6%)24 (80.0%)12 (75.0%)
Age (years, mean [range])51.2 (26–83)53.6 (39–77)49.1 (30–60)
Size (cm, mean ± SD)5.74 ± 3.175.64 ± 2.362.93 ± 2.43
Interval between MR imaging and surgery (d, mean ± SD)2.73 ± 1.992.81 ± 2.254.62 ± 7.13
Underlying Diseases
 HBV-related cirrhosis108106
 HBV carrier (not cirrhotic)52169
 Cirrhosis of other causes541
Child-Pugh Class
 A164 (99.4%)27 (90.0%)16 (100.0%)
 B1 (0.6%)3 (10.0%)0
ALT (IU/L)
 >4068 (41.2%)6 (20.0%)2 (12.5%)
AST (IU/L)
 >3584 (50.9%)7 (23.3%)1 (6.3%)
TBIL (umol/L)
 >28.011 (6.7%)4 (13.3%)1 (6.3%)
IBIL (umol/L)
 >20.06 (3.6%)5 (16.7%)1 (6.3%)
ALB (g/L)
 <354 (2.4%)2 (6.7%)0
PT (s)
 >12.842 (25.5%)4 (13.3%)0
PLT (×10^9/L)
 <10030 (18.2%)3 (10.0%)2 (12.5%)
HBsAg (COI)
 >10105 (84.8%)12 (40.0%)9 (56.3%)
AFP (ng/ml)
 >20105 (63.6%)10 (33.3%)1 (6.3%)
CEA (ng/ml)
 >3.429 (17.6%)11 (36.7%)1 (6.3%)
CA 19–9 (U/ml)
 >2268 (41.2%)15 (50.0%)0
  1. Abbreviations: HCC hepatocellular carcinoma, SD standard deviation, MR magnetic resonance, CT computed tomography, HBV hepatitis B virus, NAFLD non-alcoholic fatty liver disease, ALT alanine aminotransferase, AST aspartate aminotransferase, TBIL total bilirubin, IBIL indirect bilirubin, ALB albumin, PT prothrombin time, PLT platelet, HBsAg hepatitis B virus surface antigen, AFP alpha-fetoprotein, CEA carcinoembryonic antigen, CA 19–9 carbohydrate antigen 19–9